Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans

American Journal of Psychiatry

Volumn 171, Issue 12, 2014, Pages 1297-1309

  Wong, Ma Li ^a   Dong, Chuanhui ^a   Flores, Deborah L ^a   Ehrhart Bornstein, Monika ^a   Bornstein, Stefan ^a   Arcos Burgos, Mauricio ^a   Licinio, Julio ^a  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; DESIPRAMINE; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE; HUMAN; MALE; METHODOLOGY; MEXICAN AMERICAN; MIDDLE AGED; PHARMACOGENETICS; PREDICTIVE VALUE; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DESIPRAMINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPIGENESIS, GENETIC; FEMALE; FLUOXETINE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MEXICAN AMERICANS; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84914106962     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.12091165     Document Type: Article

References (50)

1. US Census Bureau: The Hispanic Population in the United States. Washington, DC, US Census Bureau, March 2001.
2. Rogler LH, Malgady RG, Rodriguez O: Hispanics and Mental Health: A Framework for Research. Malabar, Fla, Robert E Krieger, 1989.
3. Wong ML, Licinio J: Research and treatment approaches to depression. Nat Rev Neuro sci 2001; 2:343-351.
4. Vega WA, Kolody B, Aguilar-Gaxiola S, Alderete E, Catalano R, Caraveo-Anduaga J: Lifetime prevalence of DSM-III-R psychiatric disorders among urban and rural Mexican Americans in California. Arch Gen Psychiatry 1998; 55:771-778.
5. Mendoza R, Smith MW: The Hispanic response to psychotropic medications, in Ethnicity and Psychopharmacology. Edited by Ruiz P. Washington, DC, American Psychiatric Press, 2000, pp 55-89.
6. Marcos LR, Cancro R: Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother 1982; 36:505- 512.
7. Sánchez-Lacay JA, Lewis-Fernández R, Goetz D, Blanco C, Salmán E, Davies S, Liebowitz M: Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues. Depress Anxiety 2001; 13:118-124.
8. Alonso M, Val E, Rapaport MH: An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. J Clin Psychiatry 1997; 58:31.
9. Currier MB, Molina G, Kato M: Citalo pram treatment of major depressive disorder in Hispanic HIV and AIDS patients: A prospective study. Psychosomatics 2004; 45:210-216.
10. Fabbri C, Di Girolamo G, Serretti A: Pharmaco genetics of antidepressant drugs: An update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 487-520.
11. Niitsu T, Fabbri C, Bentini F, Serretti A: Pharmacogenetics in major depression: A comprehensive meta-analysis. Prog Neuro psychopharmacol Biol Psychiatry 2013; 45:183-194.
12. GENDEP Investigators; MARS Investigators; STAR∗D Investigators: Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome wide pharmacogenetic studies. Am J Psychiatry 2013; 170:207- 217.
13. Licinio J, Dong C, Wong ML: Novel sequence variations in the brain-derived neuro trophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66:488-497.
14. Wong ML, Dong C, Andreev V, Arcos-Burgos M, Licinio J: Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Mol Psychiatry 2012; 17:624-633.
15. Elliott E, Ezra-Nevo G, Regev L, Neufeld-Cohen A, Chen A: Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. Nat Neurosci 2010; 13: 1351-1353.
16. Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T: Antidepressants inhibit DNA methyl trans ferase 1 through reducing G9a levels. Biochem J 2012; 448:93-102.
17. Menke A, Klengel T, Binder EB: Epigenetics, depression, and antidepressant treatment. Curr Pharm Des 2012; 18:5879- 5889.
18. Massart R, Mongeau R, Lanfumey L: Beyond the mono aminergic hypothesis: neuro plasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 2012; 367:2485-2494.
19. Vialou V, Feng J, Robison AJ, Nestler EJ: Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol 2013; 53:59-87.
20. Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ: Placebo-controlled studies in depression: necessary, ethical, and feasible. Eur Arch Psychiatry Clin Neurosci 2003; 253: 22-28.
21. Kim SY, Holloway RG: Burdens and benefits of placebos in antidepressant clinical trials: A decision and cost-effectiveness analysis. Am J Psychiatry 2003; 160:1272-1276.
22. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, Lake S, Tantisira KG, Weiss ST, Wong ML: Association of a corticotropin-releasing hormone receptor 1 haplo type and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004; 9:1075-1082.
23. Hazuda HP, Comeaux PJ, Stern MP, Haffner SM, Eifler CW, Rosenthal M: A comparison of three indicators for identifying Mexican Americans in epidemiologic research: methodological findings from the San Antonio Heart Study. Am J Epidemiol 1986; 123:96-112.
24. Hamilton M: A rating scale for depression. J Neurol Neuro surg Psychiatry 1960; 23:56-62.
25. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P) version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1994.
26. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55.
27. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766-771.
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
29. Roberts RE: Reliability of the CES-D scale in different ethnic contexts. Psychiatry Res 1980; 2:125-134.
30. Zou G: A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-706.
31. Rao DC: CAT scans, PET scans, and genomic scans. Genet Epidemiol 1998; 15:1-18.
32. Breiman L, Friedman JH, Olshen RA, Stone CH: Classification and Regression Trees. Belmont, Calif, Wadsworth International Group, 1984.
33. Breiman L: Random forests. Mach Learn 2001; 45:5-32.
34. Friedman JH: Greedy function approximation: A gradient boosting machine. Ann Stat 2001; 29:1189-1232.
35. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909.
36. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I: Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta analysis. BMJ 2003; 326:1014.
37. Steffens DC, Krishnan KR, Helms MJ: Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis. Depress Anxiety 1997; 6:10-18.
38. Schmidt LG, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H, Schönhöfer PS: Adverse drug reactions to first- And second generation antidepressants: A critical evaluation of drug surveillance data. Br J Psychiatry 1986; 148:38-43.
39. Peretti S, Judge R, Hindmarch I: Safety and tolerability considerations: Tricyclic antidepressants vs selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25.
40. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J: Collaborative management to achieve treatment guidelines: Impact on depression in primary care. JAMA 1995; 273:1026-1031.
41. Kilonzo GP, Kaaya SF, Rweikiza JK, Kassam M, Moshi G: Determination of appropriate clomipramine dosage among depressed African outpatients in Dar es Salaam, Tanzania. Cent Afr J Med 1994; 40:178-182.
42. Ziegler VE, Biggs JT: Tricyclic plasma levels: effect of age, race, sex, and smoking. JAMA 1977; 238:2167-2169.
43. Hanis CL, Hewett-Emmett D, Bertin TK, Schull WJ: Origins of US Hispanics: Implications for diabetes. Diabetes Care 1991; 14: 618-627.
44. Sleath B, Rubin RH, Huston SA: Hispanic ethnicity, physician patient communication, and antidepressant adherence. Compr Psychiatry 2003; 44:198-204.
45. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S: Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004; 184:393-403.
46. Manichaikul A, Palmas W, Rodriguez CJ, Peralta CA, Divers J, Guo X, Chen WM, Wong Q, Williams K, Kerr KF, Taylor KD, Tsai MY, Goodarzi MO, Sale MM, Diez-Roux AV, Rich SS, Rotter JI, Mychaleckyj JC: Population structure of Hispanics in the United States: The multi-ethnic study of atherosclerosis. PLoS Genet 2012; 8:e1002640.
47. Dudbridge F, Gusnanto A: Estimation of significance thresholds for genome wide association scans. Genet Epidemiol 2008; 32: 227-234.
48. Bush WS, Moore JH: Chapter 11: Genome-wide association studies. PLoS Comput Biol 2012; 8:e1002822.
49. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, StringhamHM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, de Bakker PI, O'Donnell CJ, Chambers JC, Kooner JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.
50. Kathiresan S, Manning AK, Demissie S, D'Agostino RB, Surti A, Guiducci C, Gianniny L, Burtt NP, Melander O, Orho-Melander M, Arnett DK, Peloso GM, Ordovas JM, Cupples LA: A genome wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet 2007; 8(suppl 1):S17.